Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Proteomics International Laboratories Ltd. ( (AU:PIQ) ) just unveiled an announcement.
Proteomics International Laboratories has strengthened its US footprint after its Irvine, California reference laboratory secured accreditation from the College of American Pathologists, a quality benchmark regarded as the gold standard and more demanding than existing CLIA certification. Alongside the accreditation, the company has commissioned a new mass spectrometry platform to support commercialisation of its Promarker suite of precision diagnostic blood tests, initially focusing on establishing the PromarkerEso assay for esophageal adenocarcinoma ahead of a planned US launch in 2026, while also positioning the facility to run future tests such as PromarkerEndo for endometriosis, reinforcing Proteomics International’s positioning as a leading provider of high-quality precision diagnostics.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd, a subsidiary of PILL and listed on the ASX, is a medical technology company specialising in precision diagnostics and bio-analytical services based on proteomics, the large-scale study of protein structure and function. The company develops and commercialises blood-based Promarker tests, including PromarkerD for diabetic kidney disease, with a mission to improve disease treatment and patient outcomes through innovative diagnostic tools.
Average Trading Volume: 314,184
Technical Sentiment Signal: Hold
Current Market Cap: A$83.5M
Learn more about PIQ stock on TipRanks’ Stock Analysis page.